Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 8/20 | 0.58 |
| ▸ | AR | P10275 | 6/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 0.58 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.58 |
| ▸ | ESR1 | P03372 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.58 |
| ▸ | SHBG | P04278 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.57 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6514713 | 0.88 | CYP3A4 (0.70) | PGRARSLC6A4CYP3A4LMNA | |
| SCHEMBL8507978 | 0.88 | CYP3A4 (0.70) | PGRARSLC6A4CYP3A4LMNA | |
| SCHEMBL11585281 | 0.83 | PGR (0.79) | PGRARSLC6A4CYP3A4LMNA | |
| SCHEMBL25863730 | 0.83 | PGR (0.79) | PGRARSLC6A4CYP3A4LMNA | |
| SCHEMBL25863731 | 0.83 | PGR (0.79) | PGRARSLC6A4CYP3A4LMNA | |
| SCHEMBL5692407 | 0.83 | PGR (0.79) | PGRARSLC6A4CYP3A4LMNA | |
| SCHEMBL2233527 | 0.83 | PGR (0.79) | PGRARSLC6A4CYP3A4LMNA | |
| SCHEMBL3164280 | 0.83 | PGR (0.79) | PGRARSLC6A4CYP3A4LMNA | |
| SCHEMBL24103262 | 0.83 | PGR (0.68) | PGRARSLC6A4CYP3A4LMNA | |
| SCHEMBL8853266 | 0.83 | PGR (0.68) | PGRARSLC6A4CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0335545-B2 | Pharmaceutical formulations for parenteral use | UNIV FLORIDA (US) | 1998-09-23 | — | — | EP | claimed |
| EP-0327766-B1 | Redox systems for brain-targeted drug delivery | UNIV FLORIDA (US) | 1998-04-08 | — | — | EP | claimed |
| US-5024998-A | Administering in aqueous solution with cyclodextrin derivative | UNIVERSITY OF FLORIDA (US) | 1991-06-18 | — | — | US | claimed |
| US-5017566-A | Redox systems for brain-targeted drug delivery | UNIVERSITY OF FLORIDA (US) | 1991-05-21 | — | — | US | claimed |
| US-5002935-A | Inclusion Complexing Hydroxypropylcyclodextrin with a Dihydropyridine-substituted Drug | UNIVERSITY OF FLORIDA (US) | 1991-03-26 | — | — | US | claimed |
| US-4983586-A | Decreasing precipitation at injection site or in lungs or other organs by combining with hydroxypropyl-beta-cyclodextrin | UNIVERSITY OF FLORIDA (US) | 1991-01-08 | — | — | US | claimed |
| EP-0335545-A2 | Pharmaceutical formulations for parenteral use | UNIVERSITY OF FLORIDA (US) | 1989-10-04 | — | — | EP | claimed |
| EP-0327766-A2 | Redox systems for brain-targeted drug delivery | UNIVERSITY OF FLORIDA (US) | 1989-08-16 | — | — | EP | claimed |
| US-20050059615-A1 | Transmucosal dosage forms for brain-targeted steroid chemical delivery systems | IVAX CORPORATION | 2005-03-17 | — | — | US | disclosed |
| EP-0579435-B1 | Cyclodextrin complexation | CYCLOPS H F (IS) | 1999-03-17 | — | — | EP | disclosed |
| US-5472954-A | Combining cyclodextrin with polymer before adding active material | CYCLOPS H.F. (IS) | 1995-12-05 | — | — | US | disclosed |
| US-5324718-A | Complexing with natural and synthetic polymers; high speed drug release | CYCLOPS H.F. (IS) | 1994-06-28 | — | — | US | disclosed |
| EP-0579435-A1 | Cyclodextrin complexation | CYCLOPS h.f. (IS) | 1994-01-19 | — | — | EP | disclosed |
| US-4983586-A | Decreasing precipitation at injection site or in lungs or other organs by combining with hydroxypropyl-beta-cyclodextrin | UNIVERSITY OF FLORIDA (US) | 1991-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059615-A1 | Transmucosal dosage forms for brain-targeted steroid chemical delivery systems | CYP11B2, CYP11B1, HSD17B7 | PGR 521/4885AR 944/4885SLC6A4 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.